MX2023000503A - Macrociclos y su uso. - Google Patents

Macrociclos y su uso.

Info

Publication number
MX2023000503A
MX2023000503A MX2023000503A MX2023000503A MX2023000503A MX 2023000503 A MX2023000503 A MX 2023000503A MX 2023000503 A MX2023000503 A MX 2023000503A MX 2023000503 A MX2023000503 A MX 2023000503A MX 2023000503 A MX2023000503 A MX 2023000503A
Authority
MX
Mexico
Prior art keywords
macrocyclic compounds
macrocycles
cancer
present disclosure
methods
Prior art date
Application number
MX2023000503A
Other languages
English (en)
Inventor
Jingrong Jean Cui
Original Assignee
Blossomhill Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blossomhill Therapeutics Inc filed Critical Blossomhill Therapeutics Inc
Publication of MX2023000503A publication Critical patent/MX2023000503A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Abstract

La presente descripción se refiere a compuestos macrocíclicos, composiciones farmacéuticas que contienen compuestos macrocíclicos y métodos para usar compuestos macrocíclicos para tratar enfermedades, como el cáncer.
MX2023000503A 2020-07-10 2021-07-08 Macrociclos y su uso. MX2023000503A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063050559P 2020-07-10 2020-07-10
US202163143569P 2021-01-29 2021-01-29
US202163217950P 2021-07-02 2021-07-02
PCT/US2021/040859 WO2022011123A1 (en) 2020-07-10 2021-07-08 Macrocycles and their use

Publications (1)

Publication Number Publication Date
MX2023000503A true MX2023000503A (es) 2023-02-09

Family

ID=79552077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000503A MX2023000503A (es) 2020-07-10 2021-07-08 Macrociclos y su uso.

Country Status (12)

Country Link
US (1) US20230257396A1 (es)
EP (1) EP4178958A1 (es)
JP (1) JP2023532946A (es)
KR (1) KR20230037564A (es)
CN (1) CN116171279A (es)
BR (1) BR112023000463A2 (es)
CA (1) CA3187834A1 (es)
CL (1) CL2023000061A1 (es)
IL (1) IL299732A (es)
MX (1) MX2023000503A (es)
TW (1) TW202216730A (es)
WO (1) WO2022011123A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133375A1 (en) * 2022-01-05 2023-07-13 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as kinase inhibitors
WO2023240140A1 (en) * 2022-06-08 2023-12-14 Blossomhill Therapeutics, Inc. Indazole macrocycles and their use
WO2024016986A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 大环化合物及其药物组合物和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621220T3 (es) * 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
CN105408320B (zh) * 2013-03-13 2019-08-13 北京强新生物科技有限公司 用于治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
US9714258B2 (en) * 2014-01-24 2017-07-25 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1

Also Published As

Publication number Publication date
CA3187834A1 (en) 2022-01-13
KR20230037564A (ko) 2023-03-16
WO2022011123A1 (en) 2022-01-13
US20230257396A1 (en) 2023-08-17
BR112023000463A2 (pt) 2023-03-28
TW202216730A (zh) 2022-05-01
CN116171279A (zh) 2023-05-26
CL2023000061A1 (es) 2023-11-17
JP2023532946A (ja) 2023-08-01
EP4178958A1 (en) 2023-05-17
IL299732A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2023007162A (es) Macrociclos y sus usos.
MX2023000503A (es) Macrociclos y su uso.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MD4584C1 (ro) (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
CR20220207A (es) Compuestos terapéuticos y métodos de uso
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
EP1971338B8 (en) Combination of zd6474 and pemetrexed
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
PH12020500666A1 (en) Pladienolide compounds and their use
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.